PAHC Stock Analysis: Buy, Sell, or Hold?
PAHC - Phibro Animal Health Corporation Class A
$36.32
1.14 (3.24%)
▲
5d:
+5.7%
30d:
+6.7%
90d:
+8.55%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 26, 2026
2d
Get Alerted When PAHC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: PAHC shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: PAHC shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$61.67
Based on 6.5% avg growth
INTRINSIC VALUE TODAY
$38.29
5.1% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 13.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PAHC is currently trading at $36.32, which is considered extended relative to its 30-day fair value range of $33.76 to $36.09. From a valuation perspective, the stock is trading at a discount (Forward PE: 10.5) compared to its historical average (13.5). Remarkably, the market is currently pricing in an annual earnings decline of 8.1% over the next few years. This pessimistic expectation contrasts with the company's recent 15.7% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, PAHC is in a strong downtrend. The price is approaching resistance at $36.44. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.2% recently.
Market Sentiment: The stock scores a mixed 48/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $45.00 (+27.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PAHC is in a strong downtrend. The price is approaching resistance at $36.44. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.2% recently.
Market Sentiment: The stock scores a mixed 48/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $45.00 (+27.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$33.76 -
$36.09
Company Quality Score
50/100
(HOLD)
Options IV Signal
39th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
58.5%
Protect Your Profits
Holding PAHC? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- NEUTRAL: Options fairly priced (IV 39th percentile)
- NEUTRAL: Mixed technical signals (48/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.2%)
- BULLISH: Trading 27.9% below Wall St target ($45.00)
- WARNING: Composite score 50/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$33.76 -
$36.09
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$4.17
(11.5%)
Support & Resistance Levels
Support Level
$32.88
Resistance Level
$36.44
Current Trend
Strong Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.52
Wall Street Target
$45.00
(+27.9%)
Revenue Growth (YoY)
10.3%
Earnings Growth (YoY)
15.7%
Profit Margin
6.3%
Valuation Discount vs History
-8.1% cheaper
PE vs Historical
10.5 vs 13.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-8.1%
(market-implied from PE analysis)
1-Year Target
$32.33
(-8%)
2-Year Target
$29.71
(-16%)
3-Year Target
$27.31
(-22%)
3-Yr Target (if PE normalizes)
(PE: 11→14)
$35.04
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.1, Growth: 8.9%)
$86.56
(+146%)
Base:
(SPY PE: 10.5, Growth: 8.9%)
$45.37
(+29%)
Bear:
(PE: 8.9, Growth: 8.9%)
$38.57
(+10%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (15x PE), but valuation improves significantly next year (11x PE) as earnings recover.
Trailing PE: 14.89 | Current EPS (TTM): $2.38
Bull Case
$54.77
(+51%)
Analyst growth 40.5%, PE expands to 16.4
Base Case
$49.79
(+37%)
Market implied 40.5%, PE stable at 14.9
Bear Case
$24.10
(-34%)
Severe decline -20.0%, PE contracts to 12.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 10.5 to 13.5
Stabilization Target:
$45.14
(+28.3%)
PE Expansion Potential:
+28.3%
Share & Embed Analysis
Last updated: August 23, 2026 7:03 AM ET
Data refreshes hourly during market hours. Next update: 8:03 AM
Data refreshes hourly during market hours. Next update: 8:03 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PAHC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
8
Sells
Net
INSIDERS SELLING
Recent Transactions
Jack Bendheim
SELL
7040 shares
2026-04-22
Jack Bendheim
SELL
7040 shares
2026-04-16
Jack Bendheim
SELL
7040 shares
2026-04-14
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$212 | 67 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$107 | 56 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$101 | 43 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$653 | 48 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 55 HOLD |
Advanced PAHC Option Strategies
Professional options setups generated by AI based on today's PAHC price and gamma walls.
